




RealRate

PHARMACEUTICAL 2020

Sio Gene Therapies Inc.
Rank 296 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2020

Sio Gene Therapies Inc. Rank 296 of 362

The relative strengths and weaknesses of Sio Gene Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sio Gene Therapies Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 27% points. The greatest weakness of Sio Gene Therapies Inc. is the variable Net Income, reducing the Economic Capital Ratio by 231% points.

The company's Economic Capital Ratio, given in the ranking table, is -487%, being 184% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	114,584
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	43,499
Liabilities, Non-Current	22,994
Other Assets	6,844
Other Compr. Net Income	785
Other Expenses	7,663
Other Liabilities	0
Other Net Income	5,616
Property and Equipment	1,278
Research and Development	87,552
Revenues	0
Selling, General and Administrative Expense	39,466

Output Variable	Value in 1000 USD
Assets	122,706
Liabilities	66,493
Expenses	134,681
Stockholders Equity	56,213
Net Income	-129,065
Comprehensive Net Income	-128,672
Economic Capital Ratio	-487%

